Healthcare provider profile · identity verified

Armando Enrique Marull, MD

Allopathic & Osteopathic Physicians|Internal Medicine · WELLINGTON, FL · NPI 1841258829

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Armando Enrique Marull, MD received $37.70 in general payments during 2025 across 2 reported records.

Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.

Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Jardiance by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$37.70

2 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Boehringer Ingelheim Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$37.70	100.0%	2	2025

What were the payments for?

Payment categories

Category	Amount	Records
Education	$37.70	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
JARDIANCE Normalized: jardiance	Drug	Boehringer Ingelheim Pharmaceuticals, Inc.	$37.70	2	2025
Source payment records 2025-07-29 · Boehringer Ingelheim Pharmaceuticals, Inc. · $18.85 · Open Payments source 2025-07-29 · Boehringer Ingelheim Pharmaceuticals, Inc. · $18.85 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
JARDIANCE jardiance	2025	Jardiance	2024	128	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583	Jardiance · 2024 Exact normalized brand match · 1 Part D row	128	34

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Rosuvastatin Calcium	Rosuvastatin Calcium	658	214
Amlodipine Besylate	Amlodipine Besylate	502	153
Atorvastatin Calcium	Atorvastatin Calcium	448	139
Losartan Potassium	Losartan Potassium	436	138
Metformin Hcl	Metformin Hcl	389	126
Fluticasone Propionate	Fluticasone Propionate	376	127
Albuterol Sulfate Hfa	Albuterol Sulfate	332	97
Ibuprofen	Ibuprofen	330	142
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	330	42
Montelukast Sodium	Montelukast Sodium	320	104
Diclofenac Sodium	Diclofenac Sodium	314	82
Lisinopril	Lisinopril	312	97
Gabapentin	Gabapentin	308	83
Famotidine	Famotidine	293	130
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	290	185
Omeprazole	Omeprazole	273	91
Alprazolam	Alprazolam	272	52
Levothyroxine Sodium	Levothyroxine Sodium	255	92
Pantoprazole Sodium	Pantoprazole Sodium	252	94
Baclofen	Baclofen	242	95
Tamsulosin Hcl	Tamsulosin Hcl	232	77
Carvedilol	Carvedilol	229	70
Furosemide	Furosemide	185	67
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	181	60
Celecoxib	Celecoxib	170	67
Glimepiride	Glimepiride	167	54
Clopidogrel	Clopidogrel Bisulfate	156	53
Ciprofloxacin Hcl	Ciprofloxacin Hcl	155	104
Trazodone Hcl	Trazodone Hcl	155	43
Levofloxacin	Levofloxacin	152	101
Meclizine Hcl	Meclizine Hcl	152	69
Metoprolol Succinate	Metoprolol Succinate	148	47
Meloxicam	Meloxicam	147	64
Zolpidem Tartrate	Zolpidem Tartrate	145	39
Pravastatin Sodium	Pravastatin Sodium	132	38
Atenolol	Atenolol	130	45
Ropinirole Hcl	Ropinirole Hcl	130	38
Jardiance	Empagliflozin	128	34
Citalopram Hbr	Citalopram Hydrobromide	127	43
Mupirocin	Mupirocin	122	58
Clonidine Hcl	Clonidine Hcl	119	39
Tramadol Hcl	Tramadol Hcl	113	33
Alendronate Sodium	Alendronate Sodium	103	33
Donepezil Hcl	Donepezil Hcl	103	33
Hydrochlorothiazide	Hydrochlorothiazide	102	34
Simvastatin	Simvastatin	102	31
Dicyclomine Hcl	Dicyclomine Hcl	99	31
Ozempic	Semaglutide	97	17
Olmesartan Medoxomil	Olmesartan Medoxomil	93	29
Oxycodone Hcl	Oxycodone Hcl	89	suppressed
Methylprednisolone	Methylprednisolone	88	61
Ondansetron Hcl	Ondansetron Hcl	88	34
Naproxen	Naproxen	85	35
Vitamin D2	Ergocalciferol (Vitamin D2)	84	27
Cephalexin	Cephalexin	83	54
Eliquis	Apixaban	80	26
Spironolactone	Spironolactone	80	31
Mometasone Furoate	Mometasone Furoate	77	47
Clonazepam	Clonazepam	74	18
Oxybutynin Chloride	Oxybutynin Chloride	69	27
Linzess	Linaclotide	67	28
Sertraline Hcl	Sertraline Hcl	66	20
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	63	23
Metoprolol Tartrate	Metoprolol Tartrate	62	22
Fenofibrate	Fenofibrate Nanocrystallized	61	22
Pentoxifylline	Pentoxifylline	57	24
Allopurinol	Allopurinol	53	15
Amoxicillin	Amoxicillin	52	29
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	52	16
Triamcinolone Acetonide	Triamcinolone Acetonide	52	23
Novolog Flexpen	Insulin Aspart	51	14
Potassium Chloride	Potassium Chloride	51	14
Acetaminophen-Codeine	Acetaminophen With Codeine	46	16
Ketoconazole	Ketoconazole	46	15
Latanoprost	Latanoprost	45	suppressed
Valsartan	Valsartan	45	16
Nifedipine Er	Nifedipine	44	19
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	43	12
Ciprofloxacin-Dexamethasone	Ciprofloxacin Hcl/Dexameth	41	35
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	41	14
Dutasteride	Dutasteride	40	11
Fluconazole	Fluconazole	38	15
Ipratropium Bromide	Ipratropium Bromide	37	15
Sildenafil Citrate	Sildenafil Citrate	36	suppressed
Ammonium Lactate	Ammonium Lactate	35	16
Januvia	Sitagliptin Phosphate	35	13
Wixela Inhub	Fluticasone Propion/Salmeterol	34	suppressed
Acyclovir	Acyclovir	33	21
Duloxetine Hcl	Duloxetine Hcl	32	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	32	12
Ondansetron Odt	Ondansetron	32	12
Temazepam	Temazepam	32	suppressed
Tobramycin	Tobramycin	32	20
Isosorbide Mononitrate Er	Isosorbide Mononitrate	31	suppressed
Azithromycin	Azithromycin	30	25
Finasteride	Finasteride	30	11
Oxybutynin Chloride Er	Oxybutynin Chloride	30	suppressed
Prednisone	Prednisone	30	18
Propranolol Hcl	Propranolol Hcl	30	11
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	30	23
Xarelto	Rivaroxaban	30	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	29	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	28	suppressed
Hydrocortisone	Hydrocortisone	28	suppressed
Ibandronate Sodium	Ibandronate Sodium	28	suppressed
Mirtazapine	Mirtazapine	28	suppressed
Metronidazole	Metronidazole	27	18
Lovastatin	Lovastatin	26	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	25	suppressed
Paroxetine Hcl	Paroxetine Hcl	25	12
Folic Acid	Folic Acid	24	11
Glipizide	Glipizide	24	suppressed
Hydralazine Hcl	Hydralazine Hcl	24	suppressed
Breyna	Budesonide/Formoterol Fumarate	22	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	22	suppressed
Restasis	Cyclosporine	22	suppressed
Dorzolamide-Timolol	Dorzolamide Hcl/Timolol Maleat	21	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	21	suppressed
Chlorthalidone	Chlorthalidone	20	suppressed
Memantine Hcl	Memantine Hcl	20	suppressed
Ramipril	Ramipril	20	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	19	13
Enalapril Maleate	Enalapril Maleate	19	suppressed
Entresto	Sacubitril/Valsartan	19	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	19	suppressed
Felodipine Er	Felodipine	19	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	19	suppressed
Nitroglycerin	Nitroglycerin	18	suppressed
Ranolazine Er	Ranolazine	18	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	18	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	17	suppressed
Divalproex Sodium	Divalproex Sodium	17	suppressed
Farxiga	Dapagliflozin Propanediol	17	suppressed
Sulfacetamide Sodium	Sulfacetamide Sodium	17	suppressed
Tadalafil	Tadalafil	17	suppressed
Amiodarone Hcl	Amiodarone Hcl	16	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	16	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	16	suppressed
Levetiracetam	Levetiracetam	16	suppressed
Lithium Carbonate Er	Lithium Carbonate	16	suppressed
Lactulose	Lactulose	15	suppressed
Lorazepam	Lorazepam	15	suppressed
Neomycin-Polymyxin-Hc	Neomycin/Polymyxin B/Hydrocort	15	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	15	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	15	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	15	suppressed
Pregabalin	Pregabalin	15	suppressed
Procto-Med Hc	Hydrocortisone	15	suppressed
Terbinafine Hcl	Terbinafine Hcl	15	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	14	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	13	11
Telmisartan	Telmisartan	13	suppressed
Tizanidine Hcl	Tizanidine Hcl	13	suppressed
Klor-Con 10	Potassium Chloride	12	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Metformin Hcl Er	Metformin Hcl	12	suppressed
Ventolin Hfa	Albuterol Sulfate	12	suppressed
Azelastine Hcl	Azelastine Hcl	11	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	11	suppressed
Bupropion Xl	Bupropion Hcl	11	suppressed
Cefuroxime	Cefuroxime Axetil	11	suppressed
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	11	suppressed
Diclofenac Potassium	Diclofenac Potassium	11	suppressed
Neomycin-Polymyxin-Hydrocort	Neomycin/Polymyxin B/Hydrocort	11	suppressed
Novolin 70-30	Insulin Nph Hum/Reg Insulin Hm	11	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$37.70 · 2 records	Boehringer Ingelheim Pharmaceuticals, Inc.	JARDIANCE	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Jardiance play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error